Your browser doesn't support javascript.
loading
Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.
Muluneh, Benyam; Deal, Allison; Alexander, Maurice D; Keisler, Meredith D; Markey, Janell M; Neal, Jennifer M; Bernard, Stephen; Valgus, John; Dressler, Lynn G.
Afiliación
  • Muluneh B; 1 Department of Pharmacy, University of North Carolina Medical Center.
  • Deal A; 2 Eshelman School of Pharmacy, University of North Carolina.
  • Alexander MD; 3 Lineberger Comprehensive Cancer Center, University of North Carolina.
  • Keisler MD; 1 Department of Pharmacy, University of North Carolina Medical Center.
  • Markey JM; 2 Eshelman School of Pharmacy, University of North Carolina.
  • Neal JM; 1 Department of Pharmacy, University of North Carolina Medical Center.
  • Bernard S; 2 Eshelman School of Pharmacy, University of North Carolina.
  • Valgus J; 3 Lineberger Comprehensive Cancer Center, University of North Carolina.
  • Dressler LG; 4 School of Pharmacy, Virginia Commonwealth University.
J Oncol Pharm Pract ; 24(2): 98-109, 2018 Mar.
Article en En | MEDLINE | ID: mdl-27895220
Purpose Appropriate use of oral chemotherapy is a challenge for patients and clinicians. The purpose of this study was to analyze cancer patients' use of oral chemotherapies and identify opportunities to improve adherence. Methods We developed a 30-question survey to address frequency and reasons for reducing/skipping doses; sources of information for oral chemotherapy use; perceived importance of food-drug effects; and ease of understanding labeling directions. Results Ninety-three patients taking oral chemotherapies with chronic myeloid leukemia, renal cell carcinoma, breast cancer, and colorectal cancer completed the survey. This was a well-educated population with 69% (n = 62) having completed some college; 51% (n = 47) female and 59% (n = 54) older than 50 years of age. Thirty percent of patients reported forgetting to take their oral chemotherapy at least "sometimes". Younger patients (<50 vs. ≥50, p = 0.002), shorter treatment duration (<6 vs. ≥6 months p = 0.03), or with chronic myeloid leukemia (vs. other diagnoses, p = 0.015) forget to take their oral chemotherapy at higher rates. Twenty-three percent (n = 21) indicated they intentionally skipped their oral chemotherapies and 38% (n = 8) of those did not inform their physicians. Forty-one percent (n = 28) taking drugs with significant food-drug effects did not think about their last meal before taking their oral chemotherapy and 80% (n = 55) did not understand the potential interactions. Additionally, 39% (n = 36/92) never looked at labeling and 15% (n = 14/91) had difficulty understanding label directions. Conclusion There are three main barriers associated with appropriate use of oral chemotherapies: misunderstanding about the timing of drug with food; stopping drug without informing physicians; and difficulty understanding labeling directions. A multipronged approach is needed to optimize communication of directions for optimal oral chemotherapy use.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interacciones Alimento-Droga / Cumplimiento de la Medicación / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interacciones Alimento-Droga / Cumplimiento de la Medicación / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido